nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

19.09.2016 | Original Article – Clinical Oncology

Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis

verfasst von: Juan Zhou, San-Gang Wu, Jia-Yuan Sun, Feng-Yan Li, Huan-Xin Lin, Qiong-Hua Chen, Zhen-Yu He

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the clinical outcomes in patients with International Federation of Gynecology and Obstetrics (FIGO) stage I to IVA squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC) of the uterine cervix after definitive radiotherapy.

Methods

Patients with a primary diagnosis of FIGO stage I–IVA SCC, AC, and ASC of the uterine cervix who had undergone definitive beam radiation with implants or isotopes between 1988 and 2013 were identified using the Surveillance, Epidemiology, and End Results database. Univariate and multivariate Cox regression analyses were performed to analyze the effect of histologic subtype on cause-specific survival (CSS) and overall survival (OS).

Results

A total of 8751 were identified, and 86.0, 10.6, and 3.4 % of patients were SCC, AC, and ASC, respectively. AC patients were more often well differentiated, while more patients were poorly/undifferentiated in ASC subtype. A higher percentage of AC and ASC patients were stage I, and fewer had stage III compared to SCC. Univariate and multivariate Cox analyses showed that histologic subtype was an independent prognostic factor for CSS and OS. SCC subtype had a better CSS and OS compared to AC and ASC subtype. The survival between AC and ASC had no significant difference. The impact of the histologic subtype on CSS and OS was not affected by FIGO stage and the year of diagnosis.

Conclusion

AC and ASC subtypes are independent prognostic factors for cervical cancer patients treated with definitive radiotherapy. AC and ASC subtypes are associated with poor survival outcomes than those with SCC.

Baek MH, Park JY, Kim D, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH (2014) Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery. Gynecol Oncol 135(3):462–467CrossRefPubMed

Chen JL, Huang CY, Huang YS, Chen RJ, Wang CW, Chen YH, Cheng JC, Cheng AL, Kuo SH (2014) Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet Gynecol Scand 93(7):661–668CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefPubMed

dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT (2007) Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol 107(3):458–463CrossRefPubMed

Harrison TA, Sevin BU, Koechli O, Nguyen HN, Averette HE, Penalver M, Donato DM, Nadji M (1993) Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy. Gynecol Oncol 50(3):310–315CrossRefPubMed

Hsu HC, Li X, Curtin JP, Goldberg JD, Schiff PB (2015) Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy. Front Oncol 5:81CrossRefPubMedPubMedCentral

Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Hsueh S, Chen CK, Lee SP, Hong JH (2011) Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 80(2):429–436CrossRefPubMed

Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH (2012) Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys 84(2):420–427CrossRefPubMed

Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, Imai T (2010) Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther 10(10):1019–1026CrossRefPubMed

Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, Tsuda H (2009) Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer 100(9):1400–1405CrossRefPubMedPubMedCentral

Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S (2012) Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 125(2):292–296CrossRefPubMed

Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15):1154–1161CrossRefPubMed

Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, Seong J, Suh CO, Park TK (2004) Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 60(3):822–829CrossRefPubMed

Kosary CL (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10(1):31–46CrossRefPubMed

Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS (2011) Comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 120(3):439–443CrossRefPubMed

Lee JY, Lee C, Hahn S, Kim MA, Kim HS, Chung HH, Kim JW, Park NH, Song YS (2014) Prognosis of adenosquamous carcinoma compared with adenocarcinoma in uterine cervical cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 24(2):289–294CrossRefPubMed

Lee JY, Kim YT, Kim S, Lee B, Lim MC, Kim JW, Won YJ (2015) Prognosis of cervical cancer in the era of concurrent chemoradiation from national database in Korea: a comparison between squamous cell carcinoma and adenocarcinoma. PLoS ONE 10(12):e0144887CrossRefPubMedPubMedCentral

Mabuchi S, Okazawa M, Kinose Y, Matsuo K, Fujiwara M, Suzuki O, Morii E, Kamiura S, Ogawa K, Kimura T (2012a) Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy. Int J Gynecol Cancer 22(8):1389–1397CrossRefPubMed

Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K, Kimura T (2012b) Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol 127(1):114–120CrossRefPubMed

Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15):1137–1143CrossRefPubMed

Moyses HM, Morrow CP, Muderspach LI, Roman LD, Vasilev SA, Petrovich Z, Groshen SL, Klement V (1996) Residual disease in the uterus after preoperative radiotherapy and hysterectomy in stage IB cervical carcinoma. Am J Clin Oncol 19(5):433–438CrossRefPubMed

Nakamura E, Iwakawa M, Furuta R, Ohno T, Satoh T, Nakawatari M, Ishikawa K, Imadome K, Michikawa Y, Tamaki T, Kato S, Kitagawa T, Imai T (2009) Villin1, a novel diagnostic marker for cervical adenocarcinoma. Cancer Biol Ther 8(12):1146–1153CrossRefPubMed

National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed on 14 Aug 2016

Noh JM, Park W, Kim YS, Kim JY, Kim HJ, Kim J, Kim JH, Yoon MS, Choi JH, Yoon WS, Kim JY, Huh SJ (2014) Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10). Gynecol Oncol 132(3):618–623CrossRefPubMed

Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2010) Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer 102(12):1692–1698CrossRefPubMedPubMedCentral

Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18(8):1606–1613PubMed

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144–1153CrossRefPubMed

Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM (2014) Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol 135(2):208–212CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRefPubMed

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) <Katrina/Rita Population Adjustment> —Linked To County Attributes—Total US, 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission

Teke F, Yoney A, Teke M, Inal A, Urakci Z, Eren B, Zincircioglu SB, Buyukpolat MY, Ozer A, Isikdogan A, Unsal M (2014) Lack of any impact of histopathology type on prognosis in patients with early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. Asian Pac J Cancer Prev 15(6):2815–2859CrossRefPubMed

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev 25(1):16–27CrossRef

Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, Vlastos AT (2007) Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 7:164CrossRefPubMedPubMedCentral

Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy instage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Groupand Southwest Oncology Group study. J Clin Oncol 17(5):1339–1348PubMed

Winer I, Alvarado-Cabrero I, Hassan O, Ahmed QF, Alosh B, Bandyopadhyay S, Thomas S, Albayrak S, Talukdar S, Al-Wahab Z, Elshaikh MA, Munkarah A, Morris R, Ali-Fehmi R (2015) The prognostic significance of histologic type in early stage cervical cancer—a multi-institutional study. Gynecol Oncol 137(3):474–478CrossRefPubMed

Titel: Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis
verfasst von: Juan Zhou
San-Gang Wu
Jia-Yuan Sun
Feng-Yan Li
Huan-Xin Lin
Qiong-Hua Chen
Zhen-Yu He
Publikationsdatum: 19.09.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2246-9

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis